Keywords
HIV
COVID-19
Bamako
Mali
How to Cite
Abstract
Introduction :
The COVID-19 pandemic complicates global public health challenges with already pre-existing epidemics such as that of the human immunodeficiency virus.
Objective :
To study the epidemiological-clinical and evolutionary aspects of COVID-19 in people living with HIV (PvHIV) in the Infectious Diseases department of the Point G university hospital center.
Materials and method :
Cross-sectional study with retrospective collection of April 1st 2020 to March 31, 2022 on the files of hospitalized PLHIV. The data was analyzed using SPSS software.
Results :
Out of 282 hospitalized PLHIV, we collected 32 cases of COVID-19, i.e. 11.3%. The average age was 40.94 ± 10. Women accounted for 59.4%. The deterioration of the general state was the reason most found on admission (62.5%). Cough, asthenia and fever were the most frequent functional signs in 40.9%, 25% and 15.6% respectively. Oral thrush was the most found physical sign (84.3%). Half (n = 16) of the patients were at WHO clinical stage III. Severe immunosuppression (CD4 < 100 cells/mm3) was present in 5 of our patients. The average time for diagnosis of COVID-19 in hospital was 9.9 days. In 12.5% of our patients intensive care was necessary. The lethality was 59%.
Conclusion :
The deterioration of the general state was the most frequent reason for admission. Some of our patients needed intensive care.
References
1. Elbe S, David D. Sida, un enjeu global de sécurité. Politique étrangère. 2005;(1): 161-75.
2. Archives des VIH / Sida - Solthis [Internet]. [cité 4 avr 2022]. Disponible sur: https://www.solthis.org/fr/prioritesante/vih-sida/
3. World Health Organization. Coronavirus Disease (COVID-19) Situation Reports [Internet]. [cité 2 avr 2022]. Disponible sur: https://www.who.int/emergencies/diseases /novel-coronavirus-2019/situation-reports
4. Mise à jour de la situation épidémiologique de la COVID-19 en Afrique de l’Ouest et du Centre (AOC) au 20 février 2022 - World [Internet]. ReliefWeb. [cité 2 avr 2022]. Disponible sur: https://reliefweb.int/report/world/misejour-de-la-situation-pid-miologique-de-lacovid-19-en-afrique-de-louest-et-du
5. 5United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics — Fact sheet [Internet]. [cité 2 avr 2022]. Disponible sur: https://www.unaids.org/en/resources/factsheet
6. Alzate Angel JC, Martínez-Buitrago E, Posada-Vergara MP. COVID-19 and HIV. Colombia Medica 2020;1-10.
7. Centers for Disease Control and Prevention. COVID-19 and HIV | HIV Basics | HIV/AIDS | CDC [Internet]. 2022 [cité 2 avr 2022]. Disponible sur: https://www.cdc.gov/hiv/basics/covid19.html
8. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. J Med Virol 2021;93(1):194-6.
9. Tamuzi JL, Ayele BT, Shumba CS, Adetokunboh OO, Uwimana-Nicol J, Haile ZT, et al. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infectious Diseases 2020;20(1):744.
10. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020;7(5):e314-6.
11. Zhao J, Liao X, Wang H, Wei L, Xing M, Liu L, et al. Early Virus Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-19) With a History of Coinfection With Human Immunodeficiency Virus Type 1 and Hepatitis C Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; 71(16). Disponible sur: https://pubmed.ncbi.nlm.nih.gov/32270178.
12. Anti-HIV and Anti-HCV drugs are the putative inhibitors of RNA-dependentRNA polymerase activity of NSP12 of the SARS CoV-2 (COVID-19). Pharm Pharmacol Int J 2020; Volume 8(Issue 3). Disponible sur: https://medcraveonline.com/PPIJ/PPIJ-08-00292.pdf
13. Musarrat F, Chouljenko V, Dahal A, Nabi R, Chouljenko T, Jois SD, et al. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J Med Virol 2020;92(10):2087-95.
14. Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV 2020;7(8):e554-64.
15. Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2020 ;92(9):1449-59.
16. Salameh JP, Leeflang MM, Hooft L, Islam N, McGrath TA, van der Pol CB, et al. Thoracic imaging tests for the diagnosis of COVID19. Cochrane Database Syst Rev 2020 ;9 :CD013639.
17. Ngom Ndeye F, Ndiaye K, Faye Mame A, Faye Flugence A, Doutchi M, Mboup A, et al. Aspects Épidémiologiques, Cliniques, Para-cliniques et Évolutifs de l’Infection au SARS-CoV-2 Chez 22 Patients Infectés par le VIH Suivis au Centre de Traitement Ambulatoire de Fann de Dakar. Health Sci Dis. 2022; 23(2). Disponible sur: http://hsdfmsb.org/index.php/hsd/article/view/3349
18. Organisation Mondiales de la Santé. Les Personnes Déplacées Internes vaccinées contre la COVID-19 au Mali [Internet]. OMS | Bureau régional pour l’Afrique. [cité 8 avr 2022]. Disponible sur: https://www.afro.who.int/fr/news/lespersonnes-deplacees-internes-vaccineescontre-la-covid-19-au-mali
19. Médecins Sans Frontières (MSF). Face à la deuxième vague de Covid-19 au Mali, MSF relance ses activités d’urgence à Bamako [Internet]. Médecins sans frontières. [cité 8 avr 2022]. Disponible sur: https://www.msf.fr/communiquespresse/face-a-la-deuxieme-vague-de-covid19-au-mali-msf-relance-ses-activites-durgence-a-bamako
20. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020 ;323(20):2052-9.
21. Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 Among People Living with HIV: A Systematic Review. AIDS Behav 2020 ; 1-8.
22. Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS 2020; 34(13):F3-8.
23. Sixt T, Moretto F, Abdallahoui M, Chavanet P, Devilliers H, Catherine F, et al. COVID19 : une cohorte descriptive de 222 patients hospitalisés. Médecine et Maladies Infectieuses 2020 ;50(6) : S62-3.
24. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020; 382(18): 1708-20.
25. 25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020 ; 395(10223): 497-506.
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 H Hamidou Issa, Y Cissoko, I Konaté, D Ouedraogo, L Ouo Ouo, I Aden, M Soumaré Dicko, A Fofana Sidibé, O Magassouba, D Sogoba, M Kaboré, E Adéhossi, Y Toloba, S Dao